USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about gadopentetate dimeglumine. Some of the dosage forms listed on this page may not apply to the brand name Magnevist.
Applies to gadopentetate dimeglumine: intravenous solution
Intravenous route (Solution)
Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF), in patients with impaired elimination of the drugs (ie, chronic, severe renal insufficiency (GFR less than 30 mL/min/1.73 m(2)), or acute kidney injury. Avoid use of GBCAs unless the diagnostic information is essential and not available with non-contrast enhanced MRI. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. Screen all patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, age greater than 60 years, hypertension, or diabetes), perform lab testing to estimate the GFR. Do not exceed recommended dose and allow a sufficient time period for elimination prior to readministration.
Along with its needed effects, gadopentetate dimeglumine (the active ingredient contained in Magnevist) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking gadopentetate dimeglumine:
Incidence not known
Some side effects of gadopentetate dimeglumine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to gadopentetate dimeglumine: injectable solution
Cardiovascular side effects have included hypotension, hypertension, arrhythmia, tachycardia, syncope, vasodilation, pallor, nonspecific ECG changes, angina pectoris, death related to myocardial infarction, phlebitis, thrombophlebitis, deep venous thrombophlebitis, and compartment syndrome requiring surgery.
Gastrointestinal side effects have included gastrointestinal distress, stomach pain, increased salivation, abdominal pain, vomiting, constipation, thirst, anorexia, dry mouth, and diarrhea.
Nervous system side effects have included agitation, anxiety, migraine, nystagmus, drowsiness, stupor, paresthesia, and convulsions.
Ocular side effects have included diplopia, conjunctivitis, visual field defect, lacrimation disorder, eye irritation, and eye pain.
Respiratory side effects have included throat irritation, rhinorrhea, sneezing, dyspnea, wheezing, laryngismus, cough, and respiratory complaints.
Dermatologic side effects have included rash, sweating, pruritus, urticaria, facial edema, erythema multiforme, epidural necrolysis, and pustules.
Local side effects have included pain, localized warmth, and burning sensation at the injection site.
Hypersensitivity side effects have included substernal chest pain, back pain, fever, weakness, generalized coldness, generalized warmth, localized edema, tiredness, chest tightness, trembling, shivering, tension in the extremities, regional lymphangitis, pelvis pain, and anaphylactoid reactions.
Other side effects have included tinnitus and taste abnormalities.